New drug combo trial aims to boost fight against aggressive lymphoma
NCT ID NCT06692452
Summary
This study is testing whether adding the drug tazemetostat to standard CHOP chemotherapy works better for people with newly diagnosed T cell lymphoma. About 24 participants will receive the combination treatment, and researchers will measure how well the cancer responds and how long patients live without the disease getting worse. The trial is currently suspended and is not testing a cure, as patients may still need ongoing treatment or stem cell transplants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.